Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | DRD5 | P21918 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 11/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 11/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 11/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 10/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28620084 | 0.76 | MIF (0.54) | MIFDRD2DRD1DRD4DRD5 | |
| SCHEMBL2767117 | 0.74 | MIF (0.44) | MIFDRD2DRD1DRD4DRD5 | |
| SCHEMBL21158528 | 0.71 | GBA1 (0.41) | — | |
| SCHEMBL20869858 | 0.71 | GBA1 (0.41) | — | |
| SCHEMBL2935731 | 0.69 | DRD2 (0.41) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL11344678 | 0.69 | ALDH1A1 (0.40) | — | |
| SCHEMBL2499130 | 0.69 | GRM5 (0.46) | — | |
| SCHEMBL2765998 | 0.68 | MIF (0.70) | MIF | |
| SCHEMBL28582810 | 0.68 | DRD2 (0.39) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL31166754 | 0.67 | MIF (0.39) | MIFGRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795251-B2 | 3,4-dihydro-benzo[e][1,3]oxazin-2-ones | NOVARTIS AG (CH) | 2010-09-14 | — | — | US | disclosed |
| US-20090156588-A1 | 3,4-DIHYDRO-BENZO[E][1,3]OXAZIN-2-ONES | NOVARTIS AG (CH) | 2009-06-18 | — | — | US | disclosed |
| EP-1874742-A1 | 3,4-DIHYDRO-BENZO[E][1,3]OXAZIN-2-ONES | Novartis AG (CH) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006108671-A1 | 3,4-DIHYDRO-BENZO[E][1,3]OXAZIN-2-ONES | NOVARTIS AG (CH) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156588-A1 | 3,4-DIHYDRO-BENZO[E][1,3]OXAZIN-2-ONES | CYP2C8, CYP2C18, CYP4B1 | MIF 2538/4885DRD2 299/4885DRD1 563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.